Teeth may seem like static fixtures, but a new collaboration between engineers and clinicians is proving just how dynamic, ...

Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

Fintel reports that on May 21, 2025, Scotiabank downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Sector Outperform to Sector Perform. Analyst Price Forecast Suggests 244.58% ...

Myriad Genetics' RiskScore improves breast cancer screening recommendations based on individual risk assessments, as shown in a recent study.

About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.

Myriad Genetics announces findings showing the GeneSight test may reduce hospitalizations in major depressive disorder patients. Quiver AI Summary Myriad Genetics, Inc. announced that a study ...

Study published in the Journal of Clinical PsychopharmacologySALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to Neutral. Analyst Price Forecast Suggests 107.09% Upside As of April 1 ...

Quantbot Technologies LP grew its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 236.6% during the fourth quarter, HoldingsChannel reports. The institutional investor ...

StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. Several other research analysts have also ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research ...